VA
AXSM icon

Vident Advisory’s Axsome Therapeutics AXSM Stock Holding History

Vident Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355K Buy
2,099
+422
+25% +$72.9K ﹤0.01% 1419
2025
Q4 		$306K Sell
1,677
-280
-14% -$39.1K ﹤0.01% 1364
2025
Q3 		$238K Buy
+1,957
New +$220K ﹤0.01% 1504
2025
Q2 		– Sell
-3,083
Closed -$360K – 1608
2025
Q1 		$360K Buy
+3,083
New +$351K 0.01% 1195

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Advisory's AXSM Position: Q1 2026 in Review

Vident Advisory increased its Axsome Therapeutics (AXSM) stake by 25% in Q1 2026, buying an estimated $72.9K and bringing the position to 2,099 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Vident Advisory first reported a position in AXSM in Q1 2025 and has held it in 4 quarters since. The position peaked at $360K in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Vident Advisory held 2,099 shares of Axsome Therapeutics worth $355K as of Q1 2026.
  • Vident Advisory bought 422 Axsome Therapeutics shares in Q1 2026, an estimated $72.9K.
  • Axsome Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1419 holding.
  • Vident Advisory first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Vident Advisory's Axsome Therapeutics position peaked at $360K in Q1 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.